Macquarie initiated coverage of Pediatrix Medical (MD) with an Outperform rating and $18 price target Pediatrix Medical owns physician groups that staff and manages roughly one-quarter of hospital-based Neonatal Intensive Care Units in the U.S., notes the analyst. The firm considers valuation “attractive” as fundamentals stabilize and concerns around surprise billing legislation subsides, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MD:
- Pediatrix Announces Leadership Transition of Dr. Pickert
- Pediatrix Medical price target raised to $15 from $13 at Mizuho
- Pediatrix Medical price target raised to $18 from $14 at Jefferies
- Pediatrix Medical price target raised to $15 from $10 at Leerink
- Pediatrix Medical price target raised to $16 from $13 at Truist
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue